Wells Fargo & Company Athira Pharma, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATHA
# of Institutions
74Shares Held
22.8MCall Options Held
73.4KPut Options Held
97.8K-
Perceptive Advisors LLC New York, NY5.4MShares$2.27 Million0.41% of portfolio
-
Baker Bros. Advisors LP New York, NY3.15MShares$1.32 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$686,4610.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$626,9722.57% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$626,9720.29% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $15.9M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...